“An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris”, J of Skin, vol. 3, p. S1, Nov. 2019, doi: 10.25251/skin.3.supp.1.